<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Unlocking the Potential of Radiosensitizers with Patient-derived Tumor Organoids

Although radiotherapy (also called radiation therapy) is an important aspect of cancer treatment, it has limitations, including its potential for damaging healthy tissues, induction of radiotherapy resistance, requiring well-oxygenated tumors, and potentially increasing the risk for generating metastases. There remains an unmet need for ways to enhance radiotherapy.

In this blog post, we explore the value of using clinically predictive patient-derived tumor organoids (PDOs) to discover the radiosensitizing effects of existing standard-of-care (SoC) drugs or novel compounds.

Benefits and Challenges of Radiotherapy in Cancer Treatment

For more than a century, radiotherapy has been a highly valued cancer treatment option, with more than 50% of patients with cancer receiving some form of radiotherapy. Mechanistically, it works by delivering a beam of high-energy photons to the tumor, which causes both direct and indirect cellular damage, including single-strand DNA breaks (SSB), double-strand DNA breaks (DSB), base substitutions, protein cross-linking, and macromolecule cross-linking.

The direct and indirect effects of radiotherapy cause extensive DNA and cellular damage. For instance, the indirect effects of radiotherapy occur mostly due to the generation of high levels of reactive oxygen species (ROS), which can lead to the formation of highly cytotoxic DSBs and other cellular damage. These types of damage can cause cell death or permanent growth arrest. Overall, many factors have been shown to affect tumors’ response to radiotherapy, including: 

  • Cancer cell genetics/epigenetics
  • The tumor microenvironment (TME)
  • Cancer cell metabolism.

While radiotherapy has established benefits in the treatment of cancer, there are also several well-known challenges associated with the use of this therapy. As noted earlier, radiotherapy can cause substantial damage to healthy tissue, and radiotherapy has also been shown to mobilize tumor cells into the circulatory system (especially if the treatment does not kill most cancer cells present), possibly leading to a higher risk of metastasis. Radioresistance is another challenge; this occurs when cancer cells survive and proliferate despite the substantial genomic damage brought on by radiotherapy.

While the exact mechanism(s) of radioresistance remains under investigation, it is believed to involve alterations that change the expression of key genes, such as those involved in the DNA damage response (DDR) pathway, chromatin remodeling, cellular metabolism, and changes within the TME.

The Value of Radiosensitizers

Attempts at improving radiotherapy have mostly focused on enhancing the delivery of high-energy photons to the tumor (e.g., improving the precision and accuracy of delivery) and the use of compounds known as radiosensitizers, which are defined as 'any substance that makes tumor cells easier to kill with radiation therapy.’

Many SoC anti-cancer drugs are radiosensitizers, including gemcitabine, interferon-alpha, ErbB inhibitors, doxorubicin, docetaxel, cisplatin, methotrexate, 5-FU, and bleomycin (among others).

At a high level, radiosensitizers are grouped into three categories based on their structures— small molecules, macromolecules, and nanomaterials. Although each type of radiosensitizer has its own set of advantages and disadvantages, their general mechanisms fall into the following categories:

  • Inflicting additional direct DNA damage (beyond that of radiotherapy alone)
  • Inhibiting DNA repair mechanisms
  • Enhancing cell functions that improve cytotoxicity
  • Altering the expression of radiation resistance and/or radiation-sensitive genes.

The efficacy of radiosensitizers largely depends on the type and dose of the drug, the dose of radiation, and the time interval between the radiotherapy and the radiosensitizer. Despite the radiosensitizing properties of SoC drugs and progress in developing novel radiosensitizers, there is an immediate need to identify more effective radiosensitizers.

The National Cancer Institute’s (NCI) Radiation Research Program has identified the “strategic development of novel radiosensitizers” as a clinical unmet need that has been a focus of this program for several years.

The Promise of PDOs for Radiosensitizer Discovery

As described previously, 3D in vitro organoids are microscopic self-organizing structures grown from adult stem cells (ASCs), and they recapitulate the key structural and functional properties of the original source.

Optimized Hubrecht Organoid Technology (HUB) protocols have been established to develop models from both normal and diseased tissues, including tumor tissue. Patient-derived tumor organoid models can be produced either directly from patient tissue, known as PDOs, or from patient tissue that has been cultured in mice as patient-derived xenografts (PDXs), which are subsequently used to generate patient-derived xenograft organoids (PDXOs); both of which represent alternatives to working with primary patient cells.  

Such 3D in vitro tumor models faithfully recapitulate the genomic, morphological, and pathophysiological characteristics of the original patient tumor and are more easily scalable than in vivo models. That is, they are amenable to HTS approaches, and they are genetically and phenotypically stable even after long-term culturing and cryopreservation.

PDOs are important models being used to discover novel sensitivities to radiotherapy alone and in combination with potential radiosensitizers, including SoC anticancer therapies. For instance, one study exposed ten PDO models to a range of radiotherapy plus or minus a toxic dose of cisplatin or cetuximab. The combination of chemotherapy and radiotherapy resulted in increased cell death compared with single-agent treatment, and sensitivity to radiotherapy was increased in the presence of cisplatin in six of ten tested lines and in four of ten combined with cetuximab.

Furthermore, the radiosensitivity of the organoids was compared to the clinical response. For six out of seven patients, the organoid response toward radiation was similar to the clinical outcome of the patient.

Overall, PDOs are increasingly recognized as highly clinically predictive models used to develop in-depth data rapidly. These data can help develop novel approaches to radiotherapy that can lead to better cancer treatment options and outcomes for patients.

Novel PDO Radiosensitizer Screening Platform

As noted, 3D tumor organoids are amenable to HTS approaches, which can help discover the radiosensitizing effects of existing drugs or novel compounds. This approach can also be used to assess the specificity of the radiosensitizing effect by comparing organoids derived from tumor tissue with those derived from corresponding normal tissue.

Using a validated platform that is flexible, robust, and reproducible, means that clear differences in radiosensitivity across PDO models can be reliably demonstrated. An example experimental workflow is shown in Figure 1. After propagating, harvesting, and plating organoids, they are exposed to the desired compounds in the presence or absence of different levels of radiation.

Readouts are then obtained using standard biochemical viability assays, such as CellTiter-Glo (CTG) or high-content imaging (HCI), which allows a vast variety of readouts in 3D organoids, including tumor cell killing, target expression, antibody binding, and many morphological parameters. HCI can even discriminate between compounds that induce cell cycle arrest, apoptosis, and necrosis.

Figure 1: Example experimental HTS workflow for identifying radiosensitizers using PDOs.

Below are the results of an experimental study that investigated the sensitivity of 12 PDO models to radiation. PDOs were exposed to radiation levels ranging from 0 to 10 Gy. As expected, the viability of all models was 100% for the 0 Gy condition. However, a spectrum of viability was observed when the models were exposed to different radiation levels. For instance, at the highest level of radiation, viability ranged from about 15% to 100%.

Overall, the Figure 2 graph depicts the most sensitive model on the left (i.e., OV5296B) and the most insensitive model on the far right (i.e., OV5294B). This heterogeneous response profile aligns with the diversity in radiotherapy responses observed in real-world patient populations.

Figure 2: Viability analysis after exposing 12 PDO models to different levels of radiation.

Subsequently, the synergistic effects of chemoradiotherapy in combination with gemcitabine, a known radiosensitizer drug, was tested in the most sensitive and insensitive models (i.e., the two ovarian tumor organoid models OV5298B & OV5296B) plus a model with moderate sensitivity (i.e., the cervical tumor organoid model CV10946B). As shown in Figure 3, The results of this analysis demonstrate that gemcitabine increased the radiosensitivity of all three tumor organoid models, irrespective of their baseline radiosensitivity.

Figure 3: Known radiosensitizing drug gemcitabine increases radiosensitivity of both sensitive and insensitive organoid models. CTG assay was used for this study, and values are represented as relative viability compared to solvent control at 0 Gy (error bars represent SD; n=2).

Conclusion

While radiotherapy is an important tool in the cancer treatment armamentarium, there remains ample opportunity to increase its safety and efficacy. Clinically predictive PDOs, which are amenable to HTS assays, are valuable models that can be used to discover novel radiosensitizers, both for existing SoC drugs or novel compounds.

Simplify your model selection with collated mutational and gene expression profiles for tumor organoid models with this searchable organoid biobank database of PDX-derived organoid (PDXO) tumor models and patient-derived organoids (PDO) organoid models.


Related Posts